Androgen deprivation therapy for prostate cancer and risk of dementia
- PMID: 30637900
- PMCID: PMC6850189
- DOI: 10.1111/bju.14666
Androgen deprivation therapy for prostate cancer and risk of dementia
Abstract
Objectives: To study whether androgen deprivation therapy (ADT), the mainstay treatment for advanced and disseminated prostate cancer, is associated with risk of dementia.
Methods: Risk of dementia in men with prostate cancer primarily managed with ADT or watchful waiting (WW) in the Prostate Cancer Database Sweden, PCBaSe, was compared with that in prostate cancer-free men, matched on birth year and county of residency. We used Cox regression to calculate the hazard ratios (HRs) for Alzheimer's and non-Alzheimer's dementia (vascular dementia, dementia secondary to other diseases or unspecified dementias) for different types and duration of ADT and oral antiandrogens (AAs) as well as for men managed with WW.
Results: A total of 25 967 men with prostate cancer and 121 018 prostate cancer-free men were followed for a median of 4 years. In both groups 6% of the men were diagnosed with dementia. In men with prostate cancer, gonadotropin-releasing hormone agonist treatment ( HR 1.15, 95% confidence interval [CI] 1.07-1.23) and orchiectomy (HR 1.60, 95% CI 1.32-1.93) were associated with an increased risk of dementia, as compared to no treatment in prostate cancer-free men; however, this increase in risk was only observed for non-Alzheimer's dementia and occurred from year 1-4 after start of ADT. No increase in risk for any type of dementia was observed for men treated with AAs or for men on WW.
Conclusion: This population-based cohort study does not support previous observations of an increased risk of Alzheimer's dementia for men on ADT; however, there was a small increase in risk of non-Alzheimer's dementia.
Keywords: #ADT; #Dementia; #PCSM; #ProstateCancer; androgen deprivation therapy; dementia.
© 2019 The Authors BJU International published by John Wiley & Sons Ltd on behalf of BJU International.
Conflict of interest statement
None declared.
Figures
Comment in
-
Re: Androgen Deprivation Therapy for Prostate Cancer and Risk of Dementia.J Urol. 2020 Nov;204(5):1076. doi: 10.1097/JU.0000000000001248.04. Epub 2020 Aug 26. J Urol. 2020. PMID: 32845186 No abstract available.
Similar articles
-
Different androgen deprivation therapies might have a differential impact on cognition - An analysis from a population-based study using time-dependent exposure model.Cancer Epidemiol. 2020 Feb;64:101657. doi: 10.1016/j.canep.2019.101657. Epub 2020 Jan 7. Cancer Epidemiol. 2020. PMID: 31918180
-
Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer.Int J Cancer. 2016 Dec 15;139(12):2698-2704. doi: 10.1002/ijc.30403. Epub 2016 Sep 19. Int J Cancer. 2016. PMID: 27557616 Free PMC article.
-
Risk of dementia following androgen deprivation therapy for treatment of prostate cancer.Prostate Cancer Prostatic Dis. 2020 Sep;23(3):410-418. doi: 10.1038/s41391-019-0189-3. Epub 2019 Nov 29. Prostate Cancer Prostatic Dis. 2020. PMID: 31784699
-
The Risk of New Onset Dementia and/or Alzheimer Disease among Patients with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis.J Urol. 2021 Jan;205(1):60-67. doi: 10.1097/JU.0000000000001341. Epub 2020 Aug 28. J Urol. 2021. PMID: 32856962
-
Quantifying observational evidence for risk of dementia following androgen deprivation therapy for prostate cancer: an updated systematic review and meta-analysis.Prostate Cancer Prostatic Dis. 2021 Mar;24(1):15-23. doi: 10.1038/s41391-020-00267-3. Epub 2020 Aug 19. Prostate Cancer Prostatic Dis. 2021. PMID: 32814845
Cited by
-
Androgen Deprivation Therapy in High-Risk Localized and Locally Advanced Prostate Cancer.Cancers (Basel). 2022 Apr 1;14(7):1803. doi: 10.3390/cancers14071803. Cancers (Basel). 2022. PMID: 35406575 Free PMC article. Review.
-
Association between Androgen Deprivation Therapy and Risk of Dementia in Men with Prostate Cancer.Cancers (Basel). 2021 Jul 31;13(15):3861. doi: 10.3390/cancers13153861. Cancers (Basel). 2021. PMID: 34359762 Free PMC article.
-
Combining androgen deprivation and radiation therapy in the treatment of localised prostate cancer: Summary of level 1 evidence and current gaps in knowledge.Clin Transl Radiat Oncol. 2022 Jul 21;37:1-11. doi: 10.1016/j.ctro.2022.07.008. eCollection 2022 Nov. Clin Transl Radiat Oncol. 2022. PMID: 36039172 Free PMC article. Review.
-
Type of Androgen Deprivation Therapy and Risk of Dementia Among Patients With Prostate Cancer in Taiwan.JAMA Netw Open. 2020 Aug 3;3(8):e2015189. doi: 10.1001/jamanetworkopen.2020.15189. JAMA Netw Open. 2020. PMID: 32865575 Free PMC article.
-
Androgen Deprivation Therapy in Patients with Prostate Cancer is Associated with the Risk of Subsequent Alzheimer's Disease but Not with Vascular Dementia.World J Mens Health. 2022 Jul;40(3):481-489. doi: 10.5534/wjmh.210019. Epub 2021 Jun 29. World J Mens Health. 2022. PMID: 34448373 Free PMC article.
References
-
- Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR, Baltimore Longitudinal Study of A . Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001; 86: 724–31 - PubMed
-
- Moffat SD, Zonderman AB, Metter EJ et al. Free testosterone and risk for Alzheimer disease in older men. Neurology 2004; 62: 188–93 - PubMed
-
- Hogervorst E, Bandelow S, Combrinck M, Smith AD. Low free testosterone is an independent risk factor for Alzheimer's disease. Exp Gerontol 2004; 39: 1633–9 - PubMed
-
- Butchart J, Birch B, Bassily R, Wolfe L, Holmes C. Male sex hormones and systemic inflammation in Alzheimer disease. Alzheimer Dis Assoc Disord 2013; 27: 153–6 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical